Faron Reports 2022 Half-Year Financial Results
Faron Pharmaceuticals Oy (“Faron” or “Company”) Faron Reports Half-Year Financial Results, January 1 – June 30, 2022 August 25, 2022 at 2:00 am EDT / 7:00 am BST / 9:00 am EEST Summary of January – June 2022 · New data reinforces bexmarilimab’s potential to bring the promise of immunotherapy to cancer patients who are currently not benefiting from approved checkpoint inhibitors · Compelling 12-month survival data reported from Phase I/II MATINS study with 100% survival among checkpoint refractory melanoma and cholangiocarcinoma patients who benefited from